Liraglutide — compound monograph
GLP-1 receptor agonist (acylated, once-daily). Approved. The Institute assesses 7 outcomes for this compound and grades the strongest at high certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Liraglutide
- Compound class
- GLP-1 receptor agonist (acylated, once-daily)
- Assessment series
- Incretin receptor agonists
- Synonyms and codes
- NN2211 · liraglutide (INN) · Victoza (trade) · Saxenda (trade)
- Route as evaluated
- Subcutaneous once daily
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 204656-20-2
- Molecular formula
- C172H265N43O51
- Average mass
- 3751.20
- Monoisotopic mass
- 3749.03
- ATC classification
- A10BJ02
§1.3Sequence and structural notes
A 31-residue GLP-1(7-37) analogue with a single amino-acid substitution (Lys34→Arg) and a palmitic acid (C16) conjugated to Lys26 through a γ-glutamate spacer. The shorter, non-diacid fatty chain confers weaker albumin binding than semaglutide and hence a once-daily rather than once-weekly profile.
§1.4Assessment status
The Institute assesses Liraglutide across 7 indications and grades the strongest of them at high certainty. Holds a marketing authorisation for at least one indication in at least one jurisdiction.
Table 1. Assessed outcomes for Liraglutide, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Atherosclerotic cardiovascular disease and cardiovascular risk reduction | MACE hazard ratio 0.87 in type 2 diabetes at high cardiovascular risk | High | 1 |
| Obesity and overweight in adults | −8.0 % body weight at 56 weeks with 3.0 mg versus −2.6 % with placebo | High | 2 |
| Type 2 diabetes mellitus | −1.1 to −1.5 % HbA1c at 26 weeks with 1.8 mg | High | 2 |
| Adjunctive therapy in type 1 diabetes | HbA1c reduction of approximately 0.2 % with increased hypoglycaemia and hyperketonaemia | Moderate | 2 |
| Obesity in children and adolescents | BMI z-score reduction of 0.22 versus 0.01 with placebo at 56 weeks | Moderate | 1 |
| Obstructive sleep apnoea with obesity | Apnoea–hypopnoea index reduced by 12.2 events/hour versus 6.1 with placebo at 32 weeks | Moderate | 1 |
| Prediabetes and progression to type 2 diabetes | Time to onset of type 2 diabetes over 160 weeks: hazard ratio 0.21 | Moderate | 1 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.